Eligibility for icosapent ethyl in a French population of coronary outpatients with type 2 diabetes

Pierre François Sabouret; Jean-Claude Dib; Fiona Ecarnot; Maciej Banach; Nicolas Lellouche

doi:10.5114/aoms/173511

Eligibility for icosapent ethyl in a French population of coronary outpatients with type 2 diabetes

Arch Med Sci. 2023 Oct 24;19(6):1901-1903. doi: 10.5114/aoms/173511. eCollection 2023.

Authors

Pierre François Sabouret^{1

2}, Jean-Claude Dib², Fiona Ecarnot³, Maciej Banach^{4

5}, Nicolas Lellouche⁶

Affiliations

¹ Sorbonne University, ACTION Study Group, INSERM UMRS_1166, Cardiology Institute, Pitié Salpêtrière Hospital (AP-HP), France.
² Collège National des Cardiologues Français, France.
³ Department of Cardiology, University Hospital Besançon, Besançon, France.
⁴ Department of Preventive Cardiology and Lipidology, Medical University of Lodz, Lodz, Poland.
⁵ Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.
⁶ Department of Cardiology, Henri Mondor Hospital (APHP), Créteil, France.

Abstract

Introduction: We determined eligibility for icosapent ethyl (EPA) treatment in coronary artery disease (CAD).

Methods: Consecutive patients with type 2 diabetes and CAD were prospectively included from 03/2019 to 12/2020.

Results: 574 patients were included; mean age 71 years, 81% males, with a high prevalence of other risk factors (81% hypertension). Mean lipid-density lipoprotein cholesterol was 85 mg/dl, mean glycated hemoglobin HbA_1c 7.1%, mean triglycerides 148 mg/dl; 82% received statins. Based on National Lipid Association criteria, 31% would be eligible for EPA.

Conclusions: In this contemporary survey in consecutive, unselected CAD patients in daily practice, almost a third would be potentially eligible for EPA.

Keywords: cardiovascular disease; diabetes mellitus; icosapent ethyl (EPA); medical therapy; triglycerides.